News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: Phase1/1b Trial of Fruquintinib in Patients with Advanced Solid Tumors

Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC)
Lead Author: N. Arvind Dasari, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Session: e-Poster Display Session
Abstract Number: 458P
Date available: Thursday, September 17, 2020

 

Background

Fru is a highly selective, novel vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor (TKI). In the ph 3 FRESCO study (NCT02314819) that led to its approval in China, Fru 5mg daily, 3 weeks (wks) on 1 wk off, improved the median overall survival in pts with mCRC in third line and beyond when compared to placebo (9.3 v 6.6 months); hazard ratio 0.65 (P < 0.001).

Methods

This is an ongoing ph 1/1b open-label, dose escalation (esc)/exp study conducted in the US. The dose esc was previously reported with confirmation of the approved dose/schedule in China. Here we present the preliminary safety and efficacy data from pts with refractory mCRC (exp) who progressed on all standard therapies including TAS-102 and/or regorafenib (rego).

Results

To date, 24 pts have been treated; age <65 years (62.5%), Caucasian (75%), female (54.2%), and ECOG PS 1 (62.5%). Median number of prior therapies was 4 (range: 1-7), and 7 pts (29.2%) received rego, 11 (45.8%) received TAS-102 and 6 (25.0%) received both rego and TAS-102. 16 pts remain on treatment. The median duration of Fru treatment was 2.8 months (range: 0.7– 10.4). The most frequently reported treatment-related (TR) treatment emergent adverse events (TEAEs) of any grade (Gr)(≥20% of pts) were hypertension (37.5%), proteinuria (29.2%), fatigue (29.2%), hand-foot syndrome (HFS)(29.2%), diarrhea (25.0%), headache (20.8%), stomatitis (20.8%), and elevated alk phos (20.8%). 8 (33.3%) pts reported Gr ≥3 TR TEAEs. Those that occurred in ≥5% of pts were hypertension (25%), proteinuria (8.3%) and fatigue (8.3%). No Gr ≥3 HFS was seen. Preliminary efficacy in pts who had a post-baseline scan and at least 3 months of follow up or discontinued treatment early (n=14) showed stable disease in 11 pts, with a disease control rate of 78.6%.

Conclusions

Fru is generally well-tolerated in heavily pretreated pts with refractory mCRC, with less HFS compared to other VEGFR TKIs. Evidence of anticancer activity was also observed in these pts. The multi-cohort dose exp is ongoing. Fru is being further investigated in refractory mCRC in a global Ph 3 study (NCT04322539).
Clinical trial identification: NCT03251378 (first posted 16 Aug 2017).

Editorial acknowledgement: Sarah Milner, PhD (Synchrogenix) provided editorial assistance.

Legal entity responsible for the study: Hutchison MediPharma Limited.

Funding: Hutchison MediPharma Limited.

Disclosure

N.A. Dasari: Advisory/Consultancy, Research grant/Funding (institution): Hutchison MediPharma Ltd. A. Wang-Gillam: Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Esai; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: Bristol Myer Squibb; Honoraria (self), Advisory/Consultancy: Tyme; Honoraria (self), Advisory/Consultancy: Merrimack; Honoraria (self), Advisory/Consultancy: Jacobio; Research grant/Funding (institution): Barns Jewish Foundation; Research grant/Funding (institution): Pancreatic Cancer Action Network. J.M. Hubbard: Research grant/Funding (institution): Merck; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Treos Bio; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Senhwa Pharmaceuticals; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): TriOncology; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Hutchison MediPharma. A. Fernandez: Full/Part-time employment: Hutchison MediPharma International, Inc; Shareholder/Stockholder/Stock options: Hutchison China Meditech Ltd. S. Nanda: Full/Part-time employment: Hutchison MediPharma International, Inc; Shareholder/Stockholder/Stock options: Hutchison China Meditech Ltd. M. Kania: Full/Part-time employment: Hutchison MediPharma International, Inc; Shareholder/Stockholder/Stock options: Hutchison China Meditech Ltd. W.R. Schelman: Full/Part-time employment: Hutchison MediPharma International, Inc; Shareholder/Stockholder/Stock options: Hutchison China Meditech Ltd. T.S. Bekaii-Saab: Research grant/Funding (institution): Boston Biomedical; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Amgen; Advisory/Consultancy, Research grant/Funding (institution): Merck; Research grant/Funding (institution): Celgene; Advisory/Consultancy, Research grant/Funding (institution), IDMC/DSMB: Eli Lilly; Advisory/Consultancy, Research grant/Funding (institution): Ipsen; Research grant/Funding (institution): Clovis; Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics; Advisory/Consultancy, Research grant/Funding (institution): Array Biopharma; Advisory/Consultancy, Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Abgenomics; Advisory/Consultancy, Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Treosbio; Advisory/Consultancy: Sobi; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, IDMC/DSMB: Exelixis; Advisory/Consultancy, IDMC/DSMB: PanCan; Advisory/Consultancy, IDMC/DSMB: 1Globe; Advisory/Consultancy: Imugene; Advisory/Consultancy: Immuneering; Advisory/Consultancy: Sun Biopharma.